Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
18.6M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
19M
-
Shares change
-
-1.73M
-
Total reported value, excl. options
-
$9.52M
-
Value change
-
-$954K
-
Number of buys
-
11
-
Number of sells
-
-9
-
Price
-
$0.50
Significant Holders of UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) as of Q2 2024
27 filings reported holding UNCY - UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share as of Q2 2024.
UNICYCIVE THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (UNCY) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19M shares
.
Largest 10 shareholders include Vivo Capital, LLC (3.47M shares), Logos Global Management LP (3.47M shares), Nantahala Capital Management, LLC (2.82M shares), RA CAPITAL MANAGEMENT, L.P. (2.63M shares), BVF INC/IL (2.2M shares), Rosalind Advisors, Inc. (1.57M shares), VANGUARD GROUP INC (1.14M shares), Monashee Investment Management LLC (1M shares), GEODE CAPITAL MANAGEMENT, LLC (286K shares), and GOLDMAN SACHS GROUP INC (93.4K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.